DLL3, His, Cynomolgus

DLL3, His, Cynomolgus

Delta-like protein 3 (DLL3) is a transmembrane protein that belongs to the Delta/Serrate/Lag-2 (DSL) family of Notch ligands. DLL3 inhibits primary neurogenesis. May be required to divert neurons along a specific differentiation pathway. Plays a role in the formation of somite boundaries during segmentation of the paraxial mesoderm (By similarity).
Z03946
¥70,688.00

Ask us a question
Product Introduction
Species Cynomolgus
Protein Construction
DLL3 (Ala27-Ala477)
Accession # A0A2K5WSR1		 His
N-term C-term
Purity > 95% as determined by Bis-Tris PAGE
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Immobilized DLL3, His, Cynomolgus (Cat.No.: Z03946) at 0.2 μg/ml (100μl/Well) on the plate can bind Anti-DLL3 Antibody, hFc Tag
Expression System HEK293
Theoretical Molecular Weight 48.80 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 52-62 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22 μm filtered solution in 20mM Tris, 200mM NaCl, 200mM L-arginine (pH 8.5).
Reconstitution It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH2O more than 100 μg/ml.
Storage & Stability Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

Background
Target Background Delta-like ligand 3 (DLL3) is an inhibitory Notch ligand. It is highly expressed on the surface of Small cell lung cancer (SCLC) and other neuroendocrine tumors. And its expression promotes SCLC migration and invasion. DLL3 agents are evaluated in several ongoing clinical studies in SCLC and other neuroendocrine tumors.
Synonyms Delta3; DLL3; Pudgy; SCDO1; SCDO1delta3

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.